The ACTIV-4b Trial: Antithrombotics For Treatment of Outpatient COVID-19
Background: Severely ill patients diagnosed with COVID-19 have an increased risk of cardiovascular complications, especially thromboembolic events (Bikdeli 2020). The overall incidence of developing venous thromboembolism (VTE) is approximately 17%...
Marco Torres |